M
MoonLake Immunotherapeutics (MLTX)
NCM – Real Time Price. Currency in USD
18.19
-0.65 (-3.45%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
18.19
-0.65 (-3.45%)
At close: May 12, 2026, 4:00 PM EDT
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
| Name | Position |
|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board & CEO |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer |
| Joana Cortez | Associate Vice-President of Legal & Compliance |
| Luciana Marques | Associate Vice-President of HR, People and Culture |
| Mr. Matthias Bodenstedt | Chief Financial Officer |
| Mr. Nicolas Mosimann Ph.D. | General Counsel |
| Mr. Oliver Daltrop Ph.D. | Chief Technical Officer |
| Ms. Carla Bretes | Director of Investor Relations & External Communications |
| Ms. Nuala Brennan | Chief Clinical Development Officer |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 10-Q | mnlk-20260331.htm |
| 2026-04-21 | DEFA14A | ny20067252x2_defa14a.htm |
| 2026-02-25 | 10-K | mnlk-20251231.htm |
| 2026-02-23 | 8-K | ea0277910-8k_moonlake.htm |
| 2026-01-08 | 8-K | ea0272252-8k_moonlake.htm |
| 2025-11-05 | 8-K | ea0264149-8k_moonlake.htm |
| 2025-09-29 | 8-K | ea0259129-8k_moonlake.htm |
| 2025-08-05 | 10-Q | mnlk-20250630.htm |
| 2025-06-06 | 8-K | ea0245015-8k_moonlake.htm |
| 2025-05-12 | 10-Q | mnlk-20250331.htm |